WorldWideScience

Sample records for nasha obshtshaja otvetstvennost

  1. Otvetstvennost karikaturista / Gado

    Index Scriptorium Estoniae

    Gado

    2006-01-01

    Tansaania päritolu karikaturisti GADO (Godfrey Mwampembwa) seisukohti seoses hiljutise karikatuurisõjaga Taanis avaldatud islamiusulisi solvavate karikatuuride pärast. Illustratsiooniks üks GADO karikatuur

  2. Single-arm open-label study of Durolane (NASHA nonanimal hyaluronic acid) for the treatment of osteoarthritis of the thumb

    Science.gov (United States)

    Velasco, Eloisa; Ribera, Mª Victoria; Pi, Joan

    2017-01-01

    Introduction Osteoarthritis of the trapeziometacarpal (TMC) joint of the thumb – also known as rhizarthrosis – is painful and has a significant impact on quality of life. Intra-articular injection of hyaluronic acid may potentially meet the need for effective, minimally invasive intervention in patients not responding adequately to initial treatment. We aimed to confirm the safety and effectiveness of viscosupplementation with Durolane (NASHA nonanimal hyaluronic acid) in rhizarthrosis. Patients and methods This was a prospective, single-arm, multicenter, open-label study with a 6-month follow-up period. Eligible patients had Eaton–Littler grade II–III rhizarthrosis in one TMC joint with pain and visual analog scale (VAS) pain score ≥4 (scale: 0–10). A single injection of NASHA was administered to the affected TMC joint. The primary effectiveness variable was change from baseline in VAS pain score. Results Thirty-five patients (mean age 60.8 years; 85.7% female) received NASHA and completed the study. The least-squares mean change from baseline in VAS pain score over 6 months was −2.00, a reduction of 27.8% (pKapandji thumb opposition test, radial abduction, metacarpophalangeal (MCP) joint flexion, and pinch (clamp) strength. Most of these measurements showed statistically significant improvements from baseline over 6 months. Five adverse events (injection site reactions) were reported in four patients (11.4%), and there were no serious or allergic reactions. Conclusion This study suggests that viscosupplementation using NASHA is effective and well tolerated in treating the symptoms of rhizarthrosis. PMID:28392718

  3. Single-arm open-label study of Durolane (NASHA nonanimal hyaluronic acid for the treatment of osteoarthritis of the thumb

    Directory of Open Access Journals (Sweden)

    Velasco E

    2017-03-01

    Full Text Available Eloisa Velasco,1 Mª Victoria Ribera,2 Joan Pi3 1Department of Orthopedic Surgery, Hospital de Sant Joan Despí Moisés Broggi, Barcelona, Spain; 2Department of Anesthesiology, Vall d’Hebron University Hospital, Barcelona, Spain; 3Department of Orthopedics and Traumatology, Parc Taulí University Hospital, Sabadell, Barcelona, Spain Introduction: Osteoarthritis of the trapeziometacarpal (TMC joint of the thumb – also known as rhizarthrosis – is painful and has a significant impact on quality of life. Intra-articular injection of hyaluronic acid may potentially meet the need for effective, minimally invasive intervention in patients not responding adequately to initial treatment. We aimed to confirm the safety and effectiveness of viscosupplementation with Durolane (NASHA nonanimal hyaluronic acid in rhizarthrosis.Patients and methods: This was a prospective, single-arm, multicenter, open-label study with a 6-month follow-up period. Eligible patients had Eaton–Littler grade II–III rhizarthrosis in one TMC joint with pain and visual analog scale (VAS pain score ≥4 (scale: 0–10. A single injection of NASHA was administered to the affected TMC joint. The primary effectiveness variable was change from baseline in VAS pain score.Results: Thirty-five patients (mean age 60.8 years; 85.7% female received NASHA and completed the study. The least-squares mean change from baseline in VAS pain score over 6 months was –2.00, a reduction of 27.8% (p<0.001. The reduction in pain exceeded 25% as early as month 1 (26.5%, and gradual improvement was observed throughout the 6-month follow-up period. Secondary effectiveness parameters included QuickDASH (shortened version of Disabilities of the Arm, Shoulder, and Hand [DASH], Kapandji thumb opposition test, radial abduction, metacarpophalangeal (MCP joint flexion, and pinch (clamp strength. Most of these measurements showed statistically significant improvements from baseline over 6 months. Five

  4. Efectividad y seguridad de la viscosuplementación con dosis única de ácido hialurónico estabilizado de origen no animal (NASHA) para el tratamiento del dolor secundario a gonartrosis Efficacy and safety of single intra-articular injection of non-animal stabilized hyaluronic acid (NASHA) for gonarthrosis pain treatment

    OpenAIRE

    2012-01-01

    Objetivos: valorar la efectividad y seguridad de la inyección de dosis única de ácido hialurónico estabilizado de origen no animal (NASHA) para el tratamiento del dolor secundario a gonartrosis. Material y métodos: se han incluido un total de 37 pacientes afectos de gonartrosis diagnosticada previamente por el Traumatólogo/Reumatólogo en los que ha fracasado el tratamiento conservador y/o que no son tributarios de tratamiento quirúrgico. Se les ha efectuado una infiltración en dosis única de ...

  5. Efectividad y seguridad de la viscosuplementación con dosis única de ácido hialurónico estabilizado de origen no animal (NASHA para el tratamiento del dolor secundario a gonartrosis Efficacy and safety of single intra-articular injection of non-animal stabilized hyaluronic acid (NASHA for gonarthrosis pain treatment

    Directory of Open Access Journals (Sweden)

    M. M. Monerris Tabasco

    2012-10-01

    Full Text Available Objetivos: valorar la efectividad y seguridad de la inyección de dosis única de ácido hialurónico estabilizado de origen no animal (NASHA para el tratamiento del dolor secundario a gonartrosis. Material y métodos: se han incluido un total de 37 pacientes afectos de gonartrosis diagnosticada previamente por el Traumatólogo/Reumatólogo en los que ha fracasado el tratamiento conservador y/o que no son tributarios de tratamiento quirúrgico. Se les ha efectuado una infiltración en dosis única de ácido hialurónico estabilizado no animal (NASHA, Durolane®. Se han recogido datos demográficos, efectos adversos e intensidad del dolor (valorada mediante escala verbal numérica y puntuación en los cuestionarios Western Ontario and McMaster Universities Osteoartritis Index (WOMAC y Barthel -basal, a las 2 semanas, a los 3 meses y a los 6 meses de la infiltración-. Se ha considerado efectiva una disminución ≥ 30% durante más de 3 meses en las puntuaciones basales. Resultados: los pacientes son mayoritariamente mujeres (83,8%, con una edad media de 72,8 años (desviación típica -S- = 8,4 e índice de masa corporal medio (IMC 31,9 (S = 6,9. La rodilla infiltrada es izquierda en el 51,7%, derecha en el 41,4% y bilateral en el 6,9% de los pacientes. Han presentado efectos adversos en forma de artralgias bien toleradas el 11,1% de los pacientes. En base a los resultados, la infiltración con dosis única de ácido hialurónico estabilizado de origen no animal (NASHA por gonalgia de origen artrósico provoca una reducción estadísticamente significativa en la intensidad del dolor (escala verbal numérica y WOMAC y de la capacidad funcional (WOMAC en todos los intervalos valorados. Se ha producido una reducción ≥ 30% en la intensidad del dolor en el 54% (valor que coincide con la reducción en la puntuación WOMAC de dolor, en la rigidez en el 62,1% y en la capacidad funcional en el 48,6% de los pacientes. Conclusiones: en nuestros

  6. Nasha TETs "pozelenejet"? / Nikolai Klotshkov

    Index Scriptorium Estoniae

    Klotshkov, Nikolai, 1952-

    2008-01-01

    Keskkonnainvesteeringute Keskus toetas Sillamäe soojuselektrijaama projekti, mille eesmärgiks on õhusaastatuse vähendamiseks koospõletada biokütuseid ja põlevkivi, projekt algab 2008. aasta augustis ja kestab aasta

  7. Nasha "Russkaja galereja" v Madride

    Index Scriptorium Estoniae

    2005-01-01

    Kaasaegse kunsti laat ARCO Madridis. Osaleb "Vene galerii" Tallinnast näitusega TRINITY. Galerist Masha Melnikova. Osalevad Ene-Liis Semper ja Moskva kunstnikud Anton Litvin ning Bogdan Mamonov. Ene-Liis Semper näitab videokunsti, Anton Litvin fotoprojekti ja Bogdan Mamonov realistlikke portreid. Näitus märtsis Vene saatkonna galeriis Tallinnas

  8. Okinte krititsheskim vzgljadom sobstvennuju otvetstvennost v dogovorahh strahhovanija firm / Mart Mere

    Index Scriptorium Estoniae

    Mere, Mart

    2008-01-01

    Marsh Kindlustusmaakleri juhatuse esimehe arvates peaksid ettevõtted majanduskriisi ajal pöörama suuremat tähelepanu kindlustusseltside valikule ja muutma kindlustuspoliitikat, vähendades kindlustuskulutusi. Vt. samas: Kindlustus ja riskijuhtimine majanduskriisi ajal

  9. Okinte krititsheskim vzgljadom sobstvennuju otvetstvennost v dogovorahh strahhovanija firm / Mart Mere

    Index Scriptorium Estoniae

    Mere, Mart

    2008-01-01

    Marsh Kindlustusmaakleri juhatuse esimehe arvates peaksid ettevõtted majanduskriisi ajal pöörama suuremat tähelepanu kindlustusseltside valikule ja muutma kindlustuspoliitikat, vähendades kindlustuskulutusi. Vt. samas: Kindlustus ja riskijuhtimine majanduskriisi ajal

  10. "Nasha tsel - rabotat odnoi komandoi" / Paul Nelson English ; interv. Aleksei Zhigulin

    Index Scriptorium Estoniae

    English, Paul Nelson

    2003-01-01

    Mazheikiu Nafta peadirektor vastab küsimustele ettevõtte töötajatele esitatavate ülesannete, tootmise optimeerimise ja moderniseerimise, ettevõtte edukuse põhjuste, Eestis ja Lätis Mazheikiu Nafta kaubamaja avamise, naftatoodete kvaliteedi kontrolli kohta

  11. "Nasha tsel - rabotat odnoi komandoi" / Paul Nelson English ; interv. Aleksei Zhigulin

    Index Scriptorium Estoniae

    English, Paul Nelson

    2003-01-01

    Mazheikiu Nafta peadirektor vastab küsimustele ettevõtte töötajatele esitatavate ülesannete, tootmise optimeerimise ja moderniseerimise, ettevõtte edukuse põhjuste, Eestis ja Lätis Mazheikiu Nafta kaubamaja avamise, naftatoodete kvaliteedi kontrolli kohta

  12. The remote sensing composite information entropy and types of Nasha coral reef atolls%南沙珊瑚环礁的遥感复合信息熵与类型

    Institute of Scientific and Technical Information of China (English)

    刘宝银; 王岩峰

    2000-01-01

    基于南沙群岛珊瑚环礁发育指数为多指标的观点,将测度出的多项相关因子的遥感复合信息数据,细分作N1,N2,…,N10个地理事件,进行了环礁信息熵分析.表征了熵值大小与干出环礁发育指数密切相关的因子,它们依次为礁顶面积(0.319)、渴湖面积(0.324)、环礁开放度(0.336)、走向(0.551)等.就此,对干出环礁发育指数提出一个新的表达式,用以划分南沙环礁发育的开放性类型.

  13. Prezident Estonii nazval nesomnennõm pravo pravoslavnoi tserkvi na registratsiju

    Index Scriptorium Estoniae

    2002-01-01

    Presidendi kohtumisest Moskva Patriarhaadi Eesti Õigeusu Kiriku pea Korneliusega. Ilmunud ka ajalehes Nasha Zhizn (2002/Feb/18) lk. 1 ; Sillamjaeskii Vestnik (2002/Feb/16) lk. 2. Pealk. ajalehes Molodjozh Estonii (2002/Feb/15): "Nesomnennoe pravo", lk. 2

  14. Knee Viscosupplementation: Cost-Effectiveness Analysis between Stabilized Hyaluronic Acid in a Single Injection versus Five Injections of Standard Hyaluronic Acid.

    Science.gov (United States)

    Estades-Rubio, Francisco J; Reyes-Martín, Alvaro; Morales-Marcos, Victor; García-Piriz, Mercedes; García-Vera, Juan J; Perán, Macarena; Marchal, Juan A; Montañez-Heredia, Elvira

    2017-03-17

    Given the wide difference in price per vial between various presentations of hyaluronic acid, this study seeks to compare the effectiveness and treatment cost of stabilized hyaluronic acid (NASHA) in a single injection with standard preparations of hyaluronic acid (HA) in five injections in osteoarthritis (OA) of the knee. Fifty-four patients with knee osteoarthritis (Kellgren-Lawrence Grade II and III) and the Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain score greater than 7, with a homogeneous distribution of age, sex, BMI, and duration of disease, were included in this study. Patients were randomized into two groups: Group I was treated with NASHA (Durolane(®)) and Group II with HA (Go-ON(®)). Patient's evolution was followed up at the 1st, 2nd, 4th, 8th, 12th, and 26th week after treatment. A statistically significant improvement in WOMAC score was observed for patients treated with NASHA versus those who received HA at Week 26. In addition, the need for analgesia was significantly reduced at Week 26 in the NASHA-treated group. Finally, the economic analysis showed an increased cost of overall treatment with HA injections. Our data support the use of the NASHA class of products in the treatment of knee OA.

  15. Knee Viscosupplementation: Cost-Effectiveness Analysis between Stabilized Hyaluronic Acid in a Single Injection versus Five Injections of Standard Hyaluronic Acid

    Directory of Open Access Journals (Sweden)

    Francisco J. Estades-Rubio

    2017-03-01

    Full Text Available Given the wide difference in price per vial between various presentations of hyaluronic acid, this study seeks to compare the effectiveness and treatment cost of stabilized hyaluronic acid (NASHA in a single injection with standard preparations of hyaluronic acid (HA in five injections in osteoarthritis (OA of the knee. Fifty-four patients with knee osteoarthritis (Kellgren–Lawrence Grade II and III and the Western Ontario and McMaster Universities Arthritis Index (WOMAC pain score greater than 7, with a homogeneous distribution of age, sex, BMI, and duration of disease, were included in this study. Patients were randomized into two groups: Group I was treated with NASHA (Durolane® and Group II with HA (Go-ON®. Patient’s evolution was followed up at the 1st, 2nd, 4th, 8th, 12th, and 26th week after treatment. A statistically significant improvement in WOMAC score was observed for patients treated with NASHA versus those who received HA at Week 26. In addition, the need for analgesia was significantly reduced at Week 26 in the NASHA-treated group. Finally, the economic analysis showed an increased cost of overall treatment with HA injections. Our data support the use of the NASHA class of products in the treatment of knee OA.

  16. Identifying factors associated with clinical success in patients treated with NASHA®/Dx injection for fecal incontinence

    Directory of Open Access Journals (Sweden)

    Franklin H

    2016-03-01

    Full Text Available Howard Franklin,1 Andrew C Barrett,1 Ray Wolf2 1Department of Medical Affairs, Salix, a Division of Valeant Pharmaceuticals North America LLC, Bridgewater, NJ, USA; 2Department of Medical Affairs, Valeant Pharmaceuticals North America LLC, Wilton Manors, FL, USA Purpose: Injection with the bulking agent consisting of non-animal stabilized hyaluronic acid/dextranomer (NASHA®/Dx is well tolerated and efficacious for the treatment of fecal incontinence (FI; however, the patient population that may derive maximum benefit has not been established. This post hoc responder analysis assessed demographic and baseline characteristics predictive of responsiveness to NASHA/Dx treatment. Methods: Adults with a Cleveland Clinic Florida fecal incontinence score (CCFIS ≥10 were randomized to receive NASHA/Dx or sham treatment. The primary end point was response to treatment (ie, decrease from baseline of ≥50% in number of FI episodes at 6 months; a prespecified secondary end point was change in fecal incontinence quality of life (FIQL score at 6 months. Post hoc subgroup analyses were performed for baseline and demographic characteristics and prior FI treatments. Results: Overall, response to treatment was significantly greater with NASHA/Dx versus sham injection (52.7% vs 32.1%; P=0.0089. All subgroups analyzed demonstrated evidence of improvement, favoring NASHA/Dx versus sham treatment for both response to treatment and change in the FIQL coping/behavior subscale score. For the primary end point, a significantly greater percentage of patients with CCFIS ≤15, FI symptoms ≤5 years’ duration, or obstetric causes of FI responded to NASHA/Dx treatment versus patients receiving sham treatment (51.1% vs 28.3%, P=0.0169; 55.4% vs 25.7%, P=0.0026; and 53.6% vs 23.1%, P=0.0191, respectively. The mean change in the FIQL coping/behavior score significantly favored NASHA/Dx versus sham treatment for patients with CCFIS ≤15 (P=0.0371, FI symptoms ≤5 years

  17. Nonalcoholic steatohepatitis and insulin resistance in children

    Institute of Scientific and Technical Information of China (English)

    Mikage; Arata; Junya; Nakajima; Shigeo; Nishimata; Tomomi; Nagata; Hisashi; Kawashima

    2014-01-01

    Various pathological conditions can cause fatty liver in children. Nonalcoholic steatohepatitis(NASH) in children has been known since 1983. However, NASH diagnosed in childhood does not have a favorable outcome.The pathological characteristics of NASH are significantly different between children and adults. Nonalcoholic fatty liver disease(NAFLD)/NASH is accompanied by insulin resistance, which plays a pivotal role in its pathophysiology in both children and adults. In NASH,a “two-hit” model involving triglyceride accumulation(first hit) and liver damage(second hit) has been accepted. Insulin resistance was found to correlate with changes in fat levels; however, it did not correlate with fibrosis or NAFLD activity score in children. Therefore,insulin resistance may be important in the first hit.Because there is obvious familial clustering in NASH,genetic predisposition as well as environmental factors including diet might be the second hit of NAFLD/NASH.

  18. [Macrolane®: A severe case of calf cellulitis after modeling injection].

    Science.gov (United States)

    Chaput, B; Eburdery, H; Crouzet, C; Grolleau, J-L; Chavoin, J-P; Garrido, I

    2012-02-01

    In recent years, the market for resorbable injectables has been steadily expanding. The European Community's seal of approval (CE) is a sufficient guaranty to get them distributed. These injectables do not require official approval because they are considered to be "implantable medical devices" and not medicines. Macrolane(®)is a hyaluronic acid in gel form (NASHA [non-animal stabilized hyaluronic acid]) and has been on the French market since 2007. It can be injected into all areas except the face. It is highly cross-linked which, while slowing its absorption into the body, can also leave long-lasting residues. We report the first case of cellulitis after injection into the calf by a practitioner in his office.

  19. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

    Institute of Scientific and Technical Information of China (English)

    Yoshihisa Takahashi; Yurie Soejima; Toshio Fukusato

    2012-01-01

    Nonalcoholic fatty liver disease (NAFLD) is a condition in which excess fat accumulates in the liver of a patient without a history of alcohol abuse.Nonalcoholic steatohepatitis (NASH),a severe form of NAFLD,can progress to liver cirrhosis and hepatocellular carcinoma.NAFLD is regarded as a hepatic manifestation of metabolic syndrome and incidence has been increasing worldwide in line with the increased prevalence of obesity,type 2 diabetes,and hyperlipemia.Animal models of NAFLD/NASH give crucial information,not only in elucidating pathogenesis of NAFLD/NASH but also in examining therapeutic effects of various agents.An ideal model of NAFLD/NASH should correctly reflect both hepatic histopathology and pathophysiology of human NAFLD/NASH.Animal models of NAFLD/NASH are divided into genetic,dietary,and combination models.In this paper,we review commonly used animal models of NAFLD/NASH referring to their advantages and disadvantages.